Balyasny Asset Management
DMK

Balyasny Asset Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Balyasny Asset Management’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-23,179
Closed -$1.78M – 2538
2021
Q2 		$1.78M Buy
+23,179
New +$1.41M 0.01% 1059
2018
Q1 		– Sell
-3,157
Closed -$972K – 2405
2017
Q4 		$972K Buy
3,157
+300
+11% +$98.7K ﹤0.01% 1344
2017
Q3 		$1.04M Buy
+2,857
New +$1.01M ﹤0.01% 1152

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.9B AUM 36.41% 1-Year Est. Return

Balyasny Asset Management's DMK Position: Q3 2021 in Review

Balyasny Asset Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q3 2021, closing a stake of 23,179 shares — an estimated $1.78M sold.

Balyasny Asset Management first reported a position in DMK in Q3 2017 and held it in 3 quarters. The position peaked at $1.78M in Q2 2021. 52 funds tracked by Wall St. Rank hold DMK as of Q3 2021.

  • Balyasny Asset Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q3 2021 after selling out during the quarter.
  • Balyasny Asset Management sold 23,179 DMK Pharmaceuticals Corporation Common Stock shares in Q3 2021, an estimated $1.78M.
  • Balyasny Asset Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2017 and held it in 3 quarters.
  • Balyasny Asset Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $1.78M in Q2 2021.
  • 52 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q3 2021.

Based on Balyasny Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.